Table 3 Serological assay interpretation per the Mikrogen assay
IgG strip | IgM strip | IgA | Patient status | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
EBNA-1 | p18 | p23 | BZLF1 | EAs (p54, p138) | p54 | p138 | ZEBRA | p23 | ||
– | – | – | – | – | – | – | – | – | – | EBV negative |
– | – | + or – | + or – | + or – | + | + or – | + or – | + or – | Primary infection | |
– | – | + or – | + or – | + or – | + or – | + | + or – | + or – | ||
– | – | + | + | weak + or - | – | – | – | – | Past infection | |
– | – | + | + | weak + | weak + | weak + | weak + | weak + | Secondary reactivationa | |
+b | + | + | + | + | – or weak + | – or weak + | – or weak + | – or weak + | EA + BZLF1+ VCA+ | Reactivation |
– | – | + | + | weak + | weak + | weak + | weak + | weak + | High | Nasopharyngeal cancer |
EBV-associated lymphoma | ||||||||||
IgG/IgM/IgA: one isolated band (with the exception of the markers IgG EBNA-1 and IgG VCA) in only one antibody class and if all other antibody classes are negative | No definitive test result (retest after 2–3 weeks) | |||||||||